Abeona Therapeutics is back in focus after analysts cut their fair value estimate from about US$20.64 to roughly US$15.56, which meaningfully reshapes the implied upside in current models. This reset lines up with recent commentary that balances long term optimism around Zevaskyn with concern about slower commercial progress and the effect of dilution on the stock. As you read on, you will see how these price target moves fit into the broader Abeona Therapeutics story and what to watch as the...
Abeona Therapeutics Inc (ABEO) posted $13.5 million in ZivaSkin net revenue and added a Phase III-ready eosinophilic esophagitis candidate with peak sales potential exceeding $750 million.
CLEVELAND (AP) — CLEVELAND (AP) — Abeona Therapeutics Inc. (ABEO) on Monday reported a loss of $4.
Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the H.C. Wainwright 28th Annual conference. Madhav Vasanthavada, Abeona’s senior vice president
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified c
Detailed price information for Abeona Therapeutics (ABEO-Q) from The Globe and Mail including charting and trades.
CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026: Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.Morgan Stanley 2
CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the
On August 13, Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter results that captured a company scaling a genuinely new kind of medicine while working through the bumps that come with it. ZEVASKYN, its cell therapy for a severe skin disease called recessive dystrophic epidermolysis bullosa, brought in $11.4 million in revenue for the quarter, and the number […]
This is the newest page. Registered accounts read further back.